RU2008122341A - Применение ингибиторов пути комплемента для лечения глазных болезней - Google Patents
Применение ингибиторов пути комплемента для лечения глазных болезней Download PDFInfo
- Publication number
- RU2008122341A RU2008122341A RU2008122341/14A RU2008122341A RU2008122341A RU 2008122341 A RU2008122341 A RU 2008122341A RU 2008122341/14 A RU2008122341/14 A RU 2008122341/14A RU 2008122341 A RU2008122341 A RU 2008122341A RU 2008122341 A RU2008122341 A RU 2008122341A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- complement pathway
- administration
- pathway inhibitor
- complement
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Abstract
1. Способ предотвращения или облегчения глазной болезни у субъекта, включающий стадию введения ингибитора пути комплемента субъекту, нуждающемуся в таком введении. ! 2. Способ по п.1, где путь комплемента представляет собой альтернативный путь комплемента. ! 3. Способ по п.1, где глазную болезнь выбирают из группы, состоящей из ретинальной дегенерации, диабетической ретинопатии и ангиогенеза, связанного с глазной болезнью. ! 4. Способ по п.3, где субъекту требуется ингибирование неоваскуляризации, связанной с глазной болезнью, которое воздействует на хориоидальную ткань, ткань ретинального пигментированного эпителия или ретинальную ткань. ! 5. Способ по любому из пп.1-4, где ингибитор пути комплемента представляет собой антитело, белок, пептид, пептидомиметик или молекулу с низким молекулярным весом. ! 6. Способ по любому из пп.1-4, где ингибитор пути комплемента представляет собой Фактор H или его функциональный пептид. ! 7. Способ по п.1, где ингибитор пути комплемента представляет собой антитело или его связывающий фрагмент. ! 8. Способ по п.7, где ингибитор пути комплемента представляет собой фрагмент антитела, включающий Fab, Fab', F(ab')2, Fv, или одноцепочечный фрагмент Fv. ! 9. Способ по п.7, где ингибитор пути комплемента представляет собой однодоменное антитело. ! 10. Способ по п.7, где ингибитор пути комплемента представляет собой моноклональное антитело. ! 11. Способ по п.7, где ингибитор пути комплемента представляет собой химерное антитело, деимунизированное, гуманизированное, приматизированное или человеческое антитело. ! 12. Способ по п.7, где антитело специфично связывается с компонентом альтернативного пути комплемента. ! 13. Спос
Claims (29)
1. Способ предотвращения или облегчения глазной болезни у субъекта, включающий стадию введения ингибитора пути комплемента субъекту, нуждающемуся в таком введении.
2. Способ по п.1, где путь комплемента представляет собой альтернативный путь комплемента.
3. Способ по п.1, где глазную болезнь выбирают из группы, состоящей из ретинальной дегенерации, диабетической ретинопатии и ангиогенеза, связанного с глазной болезнью.
4. Способ по п.3, где субъекту требуется ингибирование неоваскуляризации, связанной с глазной болезнью, которое воздействует на хориоидальную ткань, ткань ретинального пигментированного эпителия или ретинальную ткань.
5. Способ по любому из пп.1-4, где ингибитор пути комплемента представляет собой антитело, белок, пептид, пептидомиметик или молекулу с низким молекулярным весом.
6. Способ по любому из пп.1-4, где ингибитор пути комплемента представляет собой Фактор H или его функциональный пептид.
7. Способ по п.1, где ингибитор пути комплемента представляет собой антитело или его связывающий фрагмент.
8. Способ по п.7, где ингибитор пути комплемента представляет собой фрагмент антитела, включающий Fab, Fab', F(ab')2, Fv, или одноцепочечный фрагмент Fv.
9. Способ по п.7, где ингибитор пути комплемента представляет собой однодоменное антитело.
10. Способ по п.7, где ингибитор пути комплемента представляет собой моноклональное антитело.
11. Способ по п.7, где ингибитор пути комплемента представляет собой химерное антитело, деимунизированное, гуманизированное, приматизированное или человеческое антитело.
12. Способ по п.7, где антитело специфично связывается с компонентом альтернативного пути комплемента.
13. Способ по п.12, где антитело специфично связывается с Фактором D, пропердином, Фактором B, Фактором Ba или Фактором Bb.
14. Способ по п.13, где антитело специфично связывается с Фактором D.
15. Способ по п.14, где антитело представляет собой моноклональное антитело 166-32, полученное из гибридомы, депонированной в ATCC, и обозначенной HB 12476.
16. Способ по п.14, где антитело специфично связывается с тем же эпитопом, что и моноклональное антитело 166-32, полученное из гибридомы, депонированной в ATCC, и обозначенной HB 12476.
17. Способ по п.14, где антитело представляет собой гуманизированное моноклональное антитело, выделенное из антитела 166-32, полученного из гибридомы, депонированной в ATCC, и обозначенной HB 12476.
18. Способ по п.7, где антитело специфично связывается с компонентом классического или лектинового путей комплемента.
19. Способ по п.18, где антитело специфично связывается с компонентами комплемента C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9 или с C5b-9.
20. Способ по п.18, где антитело специфично связывается с компонентом комплемента C5a.
21. Способ по п.20, где антитело представляет собой антитело 137-26, полученное из гибридомы, депонированной в ATCC, и обозначенной PTA-3650.
22. Способ по п.20, где антитело специфично связывается с тем же эпитопом, что и антитело 137-26, полученное из гибридомы, депонированной в ATCC, и обозначенной PTA-3650.
23. Способ по любому из пп.1-4 и 7-22, где ингибитор пути комплемента вводят с помощью (a) парентерального введения, перорального введения, энтерального введения или местного введения (b) с помощью биосовместимого или биодеградируемого имплантата с замедленным высвобождением; (c) с помощью имплантации инфузионного насоса; или (d) с помощью локального введения, такого как введение в стекловидное тело или субконъюнктивальное введение.
24. Способ по п.23, где местное введение осуществляется с помощью раствора для глазной примочки, глазной мази, глазного щитка или раствора глазных капель.
25. Способ по п.23, дополнительно включающий стадию введения иммуномодулирующего или иммуноподавляющего компонента указанному субъекту.
26. Способ ингибирования альтернативного пути активации комплемента у субъекта, имеющего глазную болезнь, включающий введение киРНК, специфичной для белка пути комплемента.
27. Способ ингибирования альтернативного пути активации комплемента у пациента, имеющего глазную болезнь, включающий введение нуклеиновой кислоты, кодирующей ингибитор пути комплемента.
28. Способ по любому из пп.1-4, где ингибитором пути комплемента является антитело, белок, пептид, пептидомиметик или молекула с низким молекулярным весом, который вводят с помощью (a) парентерального введения, перорального введения, энтерального введения или местного введения; (b) с помощью биосовместимого или биодеградируемого имплантата с замедленным высвобождением; (c) с помощью имплантации инфузионного насоса; или (d) с помощью локального введения, такого как введение в стекловидное тело или субконъюнктивальное введение.
29. Способ по любому из пп.1-4, где ингибитором пути комплемента является фактор Н или его функциональный пептид, который вводят с помощью (a) парентерального введения, перорального введения, энтерального введения или местного введения; (b) с помощью биосовместимого или биодеградируемого имплантата с замедленным высвобождением; (c) с помощью имплантации инфузионного насоса; или (d) с помощью локального введения, такого как введение в стекловидное тело или субконъюнктивальное введение.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73376305P | 2005-11-04 | 2005-11-04 | |
US60/733,763 | 2005-11-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010152367/15A Division RU2583927C2 (ru) | 2005-11-04 | 2010-12-21 | Применение ингибиторов пути комплемента для лечения глазных болезней |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2008122341A true RU2008122341A (ru) | 2009-12-10 |
RU2417099C2 RU2417099C2 (ru) | 2011-04-27 |
Family
ID=38023865
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008122341/15A RU2417099C2 (ru) | 2005-11-04 | 2006-11-04 | Применение ингибиторов пути комплемента для лечения глазных болезней |
RU2010152367/15A RU2583927C2 (ru) | 2005-11-04 | 2010-12-21 | Применение ингибиторов пути комплемента для лечения глазных болезней |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010152367/15A RU2583927C2 (ru) | 2005-11-04 | 2010-12-21 | Применение ингибиторов пути комплемента для лечения глазных болезней |
Country Status (29)
Country | Link |
---|---|
US (3) | US8753625B2 (ru) |
EP (4) | EP1942922A4 (ru) |
JP (7) | JP2009514888A (ru) |
KR (6) | KR20180002911A (ru) |
CN (2) | CN101355956A (ru) |
AU (1) | AU2006311803C1 (ru) |
BR (1) | BRPI0619657A2 (ru) |
CA (2) | CA2903896A1 (ru) |
CR (1) | CR10041A (ru) |
DK (1) | DK2500030T4 (ru) |
EC (1) | ECSP088500A (ru) |
ES (1) | ES2551202T5 (ru) |
HK (2) | HK1175718A1 (ru) |
HU (1) | HUE026423T2 (ru) |
IL (3) | IL190547A (ru) |
MA (1) | MA29976B1 (ru) |
MX (3) | MX337061B (ru) |
MY (1) | MY151064A (ru) |
NO (1) | NO20082483L (ru) |
NZ (2) | NZ594285A (ru) |
PH (1) | PH12013501270B1 (ru) |
PL (1) | PL2500030T5 (ru) |
PT (1) | PT2500030E (ru) |
RU (2) | RU2417099C2 (ru) |
SG (1) | SG10201804008UA (ru) |
SI (1) | SI2500030T2 (ru) |
UA (1) | UA99591C2 (ru) |
WO (1) | WO2007056227A2 (ru) |
ZA (2) | ZA200803659B (ru) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2501536C2 (ru) * | 2008-10-28 | 2013-12-20 | Джонсон Энд Джонсон Вижн Кэа, Инк. | Устройство и способ активации компонентов запитываемой энергией офтальмологической линзы |
RU2673036C2 (ru) * | 2014-02-27 | 2018-11-21 | Аллерган, Инк. | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7999082B2 (en) | 2004-02-10 | 2011-08-16 | National Jewish Medical And Research Center | Anti-factor B antibodies |
WO2006096561A2 (en) | 2005-03-04 | 2006-09-14 | Duke University | Genetic variants increase the risk of age-related macular degeneration |
CN101227924A (zh) | 2005-05-26 | 2008-07-23 | 科罗拉多大学评议会 | 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制 |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
KR20180002911A (ko) | 2005-11-04 | 2018-01-08 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
SI2044111T1 (sl) | 2006-06-21 | 2015-02-27 | Musc Foundation For Research Development | Ciljanje komplementa faktorja H za zdravljenje bolezni |
PL2698166T3 (pl) | 2006-10-10 | 2016-03-31 | Regenesance B V | Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów |
KR20160092061A (ko) | 2006-11-02 | 2016-08-03 | 제넨테크, 인크. | 인간화 항-d 인자 항체 |
CN101668773B (zh) | 2007-03-14 | 2016-08-31 | 亚力史制药公司 | 人工程化抗b因子抗体 |
EP2129681A2 (en) * | 2007-03-22 | 2009-12-09 | Novartis Ag | C5 antigens and uses thereof |
WO2009029669A1 (en) | 2007-08-27 | 2009-03-05 | Novelmed Therapeutics, Inc. | Method of inhibiting complement activation with factor bb specific antibodies |
AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
US10131706B2 (en) | 2007-08-27 | 2018-11-20 | Novelmed Therapeutics, Inc. | Anti-factor Bb antibodies |
GB0718737D0 (en) * | 2007-09-25 | 2007-11-07 | Glaxo Group Ltd | Antibodies |
CN101918444A (zh) * | 2007-11-08 | 2010-12-15 | 健泰科生物技术公司 | 抗因子b抗体及其用途 |
WO2009111701A2 (en) * | 2008-03-06 | 2009-09-11 | Case Western Reserve University | Method of treating t cell mediated disorders |
CR20170001A (es) * | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
AU2013200637B2 (en) * | 2008-04-28 | 2015-07-16 | Genentech, Inc. | Humanized anti-Factor D antibodies and uses thereof |
AU2009270020B2 (en) * | 2008-07-10 | 2014-09-25 | Regenesance B.V. | Complement antagonists and uses thereof |
PL2328616T3 (pl) | 2008-08-05 | 2015-10-30 | Novartis Ag | Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5 |
CA3045436A1 (en) | 2009-01-29 | 2010-08-05 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
RS20120461A1 (en) | 2009-07-02 | 2013-06-28 | Musc Foundation For Research Development | METHODS FOR STIMULATION OF LIVER REGENERATION |
KR20120130748A (ko) | 2009-11-05 | 2012-12-03 | 알렉시온 캠브리지 코포레이션 | 발작성 야간 혈색소뇨증, 용혈성 빈혈, 및 혈관내 및 혈관외 용혈을 수반한 질환 상태의 치료 |
WO2013022801A1 (en) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
US20130011857A1 (en) | 2010-02-12 | 2013-01-10 | Cemm Forschungszentrum Fur Molekulare Medizin Gmbh | Complement factor h for oxidative stress disease conditions |
US20130058931A1 (en) | 2010-03-11 | 2013-03-07 | University Of Louisville Research Foundation, Inc. | Methods of predicting and decreasing the risk of pregnancy loss |
SG185383A1 (en) | 2010-04-30 | 2012-12-28 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies |
ES2717912T3 (es) | 2010-05-14 | 2019-06-26 | Univ Colorado Regents | Grupos dirigidos al receptor del complemento 2 (cr2) mejorados |
WO2011163394A2 (en) | 2010-06-22 | 2011-12-29 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
KR20130036276A (ko) | 2010-06-22 | 2013-04-11 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 보체 결합 3의 C3d 조각에 대한 항체들 |
JP5907966B2 (ja) * | 2010-08-05 | 2016-04-26 | フォーサイト・ビジョン フォー・インコーポレーテッド | 埋め込み型治療デバイス |
US8915877B2 (en) | 2010-10-12 | 2014-12-23 | Emmett T. Cunningham, JR. | Glaucoma drainage device and uses thereof |
US9370444B2 (en) | 2010-10-12 | 2016-06-21 | Emmett T. Cunningham, JR. | Subconjunctival conformer device and uses thereof |
AR083677A1 (es) | 2010-11-01 | 2013-03-13 | Genentech Inc | Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica |
EP2640360A2 (en) | 2010-11-19 | 2013-09-25 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
EP2646821A4 (en) * | 2010-11-29 | 2015-09-23 | Novelmed Therapeutics Inc | NEOANTIC BODY FOR THE DIAGNOSIS OF TISSUE INJURY |
SG194780A1 (en) * | 2011-05-05 | 2013-12-30 | Wellstat Immunotherapeutics Llc | Complement factor b analogs and their uses |
JP6522337B2 (ja) * | 2011-05-11 | 2019-05-29 | アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. | 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用 |
US10588879B2 (en) * | 2011-08-01 | 2020-03-17 | Aurin Biotech Inc. | Treatment of age-related macular degeneration |
CA2859493A1 (en) | 2011-12-21 | 2013-06-27 | Novartis Ag | Compositions and methods for antibodies targeting factor p |
WO2013126006A1 (en) * | 2012-02-20 | 2013-08-29 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement c5 |
US9540626B2 (en) | 2012-03-19 | 2017-01-10 | The Trustees Of The University Of Pennsylvania | Regulator of complement activation and uses thereof |
FR2988298A1 (fr) * | 2012-03-23 | 2013-09-27 | Lfb Biotechnologies | Facteur h pour son utilisation comme molecule antioxydante |
CA2869473C (en) | 2012-04-03 | 2020-06-09 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-factor bb antibodies and uses thereof |
US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
EP2855529A4 (en) | 2012-05-24 | 2015-12-09 | Alexion Pharma Inc | HUMANIZED ANTI-FACTOR B ANTIBODIES |
AU2013277154A1 (en) * | 2012-06-20 | 2014-12-18 | Jonathan E. Grob | Complement pathway modulators and uses thereof |
KR102073312B1 (ko) * | 2012-06-27 | 2020-02-05 | 엘지전자 주식회사 | 당뇨망막병증 진단용 마커 및 이의 용도 |
CN102743371A (zh) * | 2012-07-26 | 2012-10-24 | 山东省眼科研究所 | 一种治疗视网膜新生血管性疾病的药物 |
US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
WO2014028865A1 (en) | 2012-08-17 | 2014-02-20 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
US9926366B2 (en) | 2012-10-04 | 2018-03-27 | Novelmed Therapeutics, Inc. | Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies |
CA2891673A1 (en) | 2012-11-15 | 2014-05-22 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
KR101638931B1 (ko) * | 2013-01-31 | 2016-07-12 | 서울대학교산학협력단 | 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법 |
EP2968113B8 (en) | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
EP2970269B1 (en) | 2013-03-14 | 2017-04-19 | Novartis AG | 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases |
WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
CA2907681C (en) | 2013-03-28 | 2022-11-22 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
BR112015026513A2 (pt) | 2013-04-17 | 2017-07-25 | Pfizer | derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares |
US20150017163A1 (en) | 2013-07-12 | 2015-01-15 | Ophthotech Corporation | Methods for Treating or Preventing Ophthalmological Conditions |
CN107318267B (zh) | 2013-08-12 | 2021-08-17 | 豪夫迈·罗氏有限公司 | 用于治疗补体相关的病症的组合物和方法 |
US20160237146A1 (en) * | 2013-10-07 | 2016-08-18 | Massachusetts Eye And Ear Infirmary | Methods of Preventing or Reducing Photoreceptor Cell Death |
EP3089963A1 (en) | 2013-10-30 | 2016-11-09 | Novartis AG | 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof |
JP2017502023A (ja) * | 2013-12-24 | 2017-01-19 | ノーベルメッド セラピューティクス インコーポレイテッド. | 眼疾患を治療する組成物および方法 |
BR112016025312A2 (pt) | 2014-05-01 | 2017-10-17 | Genentech Inc | variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem |
EP4223317A3 (en) | 2014-06-12 | 2023-09-27 | RA Pharmaceuticals, Inc. | Modulation of complement activity |
US9474756B2 (en) | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US10112993B2 (en) * | 2014-08-20 | 2018-10-30 | Stichting Sanquin Bloedvoorziening | Factor H potentiating antibodies and uses thereof |
EP3218403B1 (en) | 2014-11-10 | 2020-05-13 | F.Hoffmann-La Roche Ag | Anti-interleukin-33 antibodies and uses thereof |
SI3250230T1 (sl) | 2015-01-28 | 2022-01-31 | Ra Pharmaceuticals, Inc. | Modulatorji aktivnosti komplementa |
RU2727411C2 (ru) * | 2015-09-24 | 2020-07-21 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Композиция и способ для лечения заболевания, опосредованного комплементом |
CN117503905A (zh) | 2015-10-07 | 2024-02-06 | 阿佩利斯制药有限公司 | 给药方案 |
CN108472382A (zh) | 2015-10-30 | 2018-08-31 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体变体缀合物及其用途 |
ES2772696T3 (es) | 2015-10-30 | 2020-07-08 | Hoffmann La Roche | Procedimientos de medición de la actividad del factor D y la potencia de los inhibidores del factor D |
JP2018534930A (ja) | 2015-10-30 | 2018-11-29 | ジェネンテック, インコーポレイテッド | 抗d因子抗体及びコンジュゲート |
FI3685847T3 (fi) | 2015-12-16 | 2023-04-03 | Ra Pharmaceuticals Inc | Komplementtiaktiivisuuden modulaattoreita |
US11072661B2 (en) | 2015-12-23 | 2021-07-27 | Sorbonne Universite | Agents that inhibit the binding of CFH to CD11 b/CD18 and uses thereof |
AU2017210042B2 (en) | 2016-01-20 | 2021-01-21 | 396419 B.C. Ltd. | Compositions and methods for inhibiting Factor D |
KR20190003951A (ko) | 2016-04-04 | 2019-01-10 | 바이오버라티브 유에스에이 인코포레이티드 | 항-보체 인자 bb 항체 및 이의 용도 |
UA124734C2 (uk) | 2016-06-14 | 2021-11-10 | Рідженерон Фармасьютікалз, Інк. | Антитіло проти с5 і його застосування |
BR112019011053A2 (pt) | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
JP7101684B2 (ja) * | 2017-01-30 | 2022-07-15 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 一価の抗プロペルジン抗体および抗体断片 |
IL268601B1 (en) | 2017-02-10 | 2024-03-01 | Univ Pennsylvania | Antibodies against factor D and their uses |
CA3059304A1 (en) | 2017-04-07 | 2018-10-11 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
AU2018250695A1 (en) | 2017-04-14 | 2019-11-07 | Kodiak Sciences Inc. | Complement factor D antagonist antibodies and conjugates thereof |
CN117327187A (zh) | 2017-07-11 | 2024-01-02 | 亚力兄制药公司 | 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 |
CN111527105A (zh) * | 2017-10-11 | 2020-08-11 | 美国比奥维拉迪维股份有限公司 | 诱导补体活性的方法 |
US20210000927A1 (en) | 2017-12-04 | 2021-01-07 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
JP2021506241A (ja) | 2017-12-13 | 2021-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 抗c5抗体組み合わせ物およびその使用 |
GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
CA3093356A1 (en) | 2018-04-03 | 2019-10-10 | Ngm Biopharmaceuticals, Inc. | C3-binding agents and methods of use thereof |
US20210246507A1 (en) * | 2018-05-10 | 2021-08-12 | The University Of Manchester | Methods for assessing macular degeneration |
EP3586865A1 (en) * | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
EP3934675A2 (en) | 2019-03-08 | 2022-01-12 | RA Pharmaceuticals, Inc. | Zilucoplan as deep tissue penetrating c5 inhibitor |
CA3134614A1 (en) | 2019-03-29 | 2020-10-08 | Ra Pharmaceuticals, Inc. | Complement modulators and related methods |
TW202106290A (zh) | 2019-04-24 | 2021-02-16 | 美商Ra製藥公司 | 用於調節補體活性之組成物及方法 |
JP2022541275A (ja) | 2019-07-17 | 2022-09-22 | ジェミニ・セラピューティクス・サブ・インコーポレイテッド | H因子増強性抗体及びその使用 |
KR102428619B1 (ko) | 2019-09-25 | 2022-08-04 | 대구가톨릭대학교산학협력단 | 망막병증 치료용 약물 방출 콘택트렌즈 및 이의 제조방법 |
AU2021236306A1 (en) | 2020-03-13 | 2022-09-15 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
AU2021261257A1 (en) | 2020-04-20 | 2022-12-22 | Genzyme Corporation | Humanized anti-complement factor Bb antibodies and uses thereof |
CN114686481B (zh) * | 2020-12-31 | 2023-08-15 | 北京键凯科技股份有限公司 | 一种抑制cfd表达的干扰rna及其制备方法和应用 |
WO2024006902A2 (en) * | 2022-06-30 | 2024-01-04 | Iveric Bio, Inc. | Sustained release silica hydrogel composites for treating ophthalmological conditions and methods of using same |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5022A (en) * | 1847-03-20 | Alfred stillman | ||
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
CA1319120C (en) | 1985-04-01 | 1993-06-15 | John Henry Kenten | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5256642A (en) * | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
AU660629B2 (en) | 1990-10-01 | 1995-07-06 | University Of Connecticut, The | Targeting viruses and cells for selective internalization by cells |
WO1992005793A1 (en) | 1990-10-05 | 1992-04-16 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
AU660297B2 (en) | 1990-11-09 | 1995-06-22 | Stephen D. Gillies | Cytokine immunoconjugates |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
AP257A (en) | 1991-04-26 | 1993-06-03 | Surface Active Ltd | A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy. |
ATE199647T1 (de) | 1991-05-14 | 2001-03-15 | Univ Connecticut | Gerichtete abgabe von genen, die immunogene proteine kodieren |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
WO1992022635A1 (en) | 1991-06-05 | 1992-12-23 | University Of Connecticut | Targeted delivery of genes encoding secretory proteins |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
ATE239506T1 (de) | 1992-03-05 | 2003-05-15 | Univ Texas | Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren |
EP0633943A4 (en) | 1992-04-03 | 1997-05-02 | Alexander T Young | GENTHERAPY USING TARGETED VIRAL VECTORS. |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
ATE182651T1 (de) | 1992-06-09 | 1999-08-15 | Hoppe Ag | Riegel und türschloss |
US5456909A (en) * | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
JPH08501085A (ja) | 1992-08-26 | 1996-02-06 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗腫瘍剤としてのサイトカインip−10の利用 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
WO1994008598A1 (en) | 1992-10-09 | 1994-04-28 | Advanced Tissue Sciences, Inc. | Liver reserve cells |
EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5861156A (en) * | 1993-01-08 | 1999-01-19 | Creative Biomolecules | Methods of delivering agents to target cells |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
US5856300A (en) * | 1994-05-12 | 1999-01-05 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
US5627264A (en) * | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
CA2186108A1 (en) * | 1994-03-23 | 1995-09-28 | Scott A. Rollins | Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation |
US5534615A (en) * | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
WO2000037638A2 (en) | 1998-12-22 | 2000-06-29 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
WO2001004311A1 (en) | 1999-07-07 | 2001-01-18 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US5681736A (en) * | 1994-10-05 | 1997-10-28 | Antex Biologics, Inc. | Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
JPH11514853A (ja) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたaavベクター |
AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
CA2248868A1 (en) | 1996-03-22 | 1997-09-25 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
WO2002008284A2 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
US20050197285A1 (en) * | 1997-03-07 | 2005-09-08 | Rosen Craig A. | Human secreted proteins |
US6472520B2 (en) * | 1997-03-21 | 2002-10-29 | The Trustees Of Columbia University In The City Of New York | Rat PEG-3 promoter |
CN100387621C (zh) | 1997-04-14 | 2008-05-14 | 麦可麦脱股份公司 | 抗人抗原受体的新的生产方法及其用途 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
DE69835524T2 (de) * | 1997-08-26 | 2007-04-05 | Amgen Fremont Inc. | Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg |
US6410708B1 (en) * | 1997-11-21 | 2002-06-25 | Genentech, Inc. | Nucleic acids encoding A-33 related antigen polypeptides |
US6642051B1 (en) | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
EP1992633A1 (en) | 1997-11-03 | 2008-11-19 | Human Genome Sciences, Inc. | VEGI, an inhibitor of angiogenesis and tumor growth |
US6595142B2 (en) | 1997-11-13 | 2003-07-22 | M.C.M. Holding A/S | Floor for a transport means and profiles for the construction thereof as well as a vehicle provided with such a floor |
US8007798B2 (en) * | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
US7282565B2 (en) * | 1998-03-20 | 2007-10-16 | Genentech, Inc. | PRO362 polypeptides |
US7419663B2 (en) * | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
US7192589B2 (en) * | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
US8088386B2 (en) * | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
ES2305608T3 (es) | 1997-11-21 | 2008-11-01 | Genentech, Inc. | Antigenos tipo a-33 y sus utilizaciones farmacologicas. |
CA2320625A1 (en) * | 1998-02-09 | 1999-08-12 | Human Genome Sciences, Inc. | 45 human secreted proteins |
US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
US7112327B2 (en) * | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
ES2317689T3 (es) * | 1998-02-20 | 2009-04-16 | Genentech, Inc. | Inhibidores de la activacion del complemento. |
ES2312205T3 (es) | 1998-03-10 | 2009-02-16 | Genentech, Inc. | Nuevo polipeptido y acidos nucleicos que lo codifican. |
EP1108019A2 (en) | 1998-08-27 | 2001-06-20 | Incyte Pharmaceuticals, Inc. | Protein transport-associated molecules |
CA2348757A1 (en) | 1998-12-16 | 2000-06-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
KR20010103046A (ko) | 1999-03-08 | 2001-11-17 | 제넨테크, 인크. | 면역 관련 질환 치료용 조성물 및 치료 방법 |
EP2292761A1 (en) | 1999-03-11 | 2011-03-09 | Merck Serono S.A. | Vascular adhesion molecules and modulation of their function |
US6642353B1 (en) * | 1999-03-17 | 2003-11-04 | Chugai Seiyaku Kabushiki Kaisha | Peptide ligands for the erythropoietin receptor |
EP1234030A4 (en) | 1999-11-19 | 2003-05-07 | Human Genome Sciences Inc | 18 HUMAN SECRETED PROTEINS |
CA2391455A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6821775B1 (en) * | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
ES2329010T3 (es) | 2000-03-23 | 2009-11-20 | Genentech, Inc. | Inhibidores anti-c2/c2a de la activacion del complemento. |
ES2316446T3 (es) * | 2000-04-29 | 2009-04-16 | University Of Iowa Research Foundation | Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular. |
EP1309620A2 (en) | 2000-06-23 | 2003-05-14 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
PT1325033E (pt) * | 2000-10-10 | 2010-04-15 | Genentech Inc | Inibição da activação do complemento c5 para o tratamento e a prevenção da rejeição diferida de um xenoenxertos ou de uma rejeição vascular aguda |
GEP20063752B (en) | 2000-10-13 | 2006-02-27 | Biogen Inc | Humanized Anti-LT-Beta-R Antibodies |
US20040077575A1 (en) * | 2002-01-11 | 2004-04-22 | Giordano Giovan Giacomo | Inhibition of pathological angiogenesis in vivo |
US6867189B2 (en) | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
JP4958387B2 (ja) * | 2001-08-17 | 2012-06-20 | ジェネンテック, インコーポレイテッド | C5bの形成を妨害することなくc5及びc5aに結合する補体経路阻害剤 |
AR040778A1 (es) | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). |
AU2003258714A1 (en) | 2002-09-06 | 2004-03-29 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
US7816497B2 (en) * | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
JP2006518749A (ja) * | 2003-02-21 | 2006-08-17 | タノックス インコーポレーテッド | 虚血再灌流障害に伴う組織損傷を予防及び治療するための方法 |
RU2232991C1 (ru) | 2003-04-09 | 2004-07-20 | Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" | Способ определения функциональной активности фактора d комплемента человека |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
WO2005014849A2 (en) * | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
WO2005025509A2 (en) | 2003-09-11 | 2005-03-24 | Board Of Regents, The University Of Texas System | Methods and materials for treating autoimmune diseases and conditions |
JP2007527865A (ja) * | 2003-09-12 | 2007-10-04 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体 |
US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
JP2008520242A (ja) * | 2004-11-18 | 2008-06-19 | イェール ユニバーシティ | 視覚障害を処置するための方法および組成物 |
WO2006071856A2 (en) | 2004-12-23 | 2006-07-06 | Glycofi, Inc. | Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
US8088579B2 (en) * | 2005-02-14 | 2012-01-03 | University Of Iowa Research Foundation | Complement factor H for diagnosis of age-related macular degeneration |
BRPI0617186A2 (pt) * | 2005-10-08 | 2011-07-19 | Potentia Pharmaceuticals Inc | uso de análogo de compstatina, implante ocular, micropartìcula ou nanopartìcula, composição, composto multivalente, ácido nucléico, vetor de expressão, célula hospedeira recombinante, proteìna de fusão e método de produção e teste |
KR20180002911A (ko) | 2005-11-04 | 2018-01-08 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
KR20160092061A (ko) * | 2006-11-02 | 2016-08-03 | 제넨테크, 인크. | 인간화 항-d 인자 항체 |
AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
-
2006
- 2006-11-04 KR KR1020177037729A patent/KR20180002911A/ko not_active Application Discontinuation
- 2006-11-04 EP EP06836941A patent/EP1942922A4/en not_active Withdrawn
- 2006-11-04 NZ NZ594285A patent/NZ594285A/xx not_active IP Right Cessation
- 2006-11-04 US US12/092,346 patent/US8753625B2/en not_active Expired - Fee Related
- 2006-11-04 AU AU2006311803A patent/AU2006311803C1/en not_active Ceased
- 2006-11-04 MX MX2011003503A patent/MX337061B/es unknown
- 2006-11-04 DK DK12172001.5T patent/DK2500030T4/en active
- 2006-11-04 RU RU2008122341/15A patent/RU2417099C2/ru not_active IP Right Cessation
- 2006-11-04 ZA ZA200803659A patent/ZA200803659B/xx unknown
- 2006-11-04 CN CNA2006800504810A patent/CN101355956A/zh active Pending
- 2006-11-04 MX MX2016001813A patent/MX360959B/es unknown
- 2006-11-04 JP JP2008539095A patent/JP2009514888A/ja not_active Withdrawn
- 2006-11-04 CA CA2903896A patent/CA2903896A1/en not_active Abandoned
- 2006-11-04 MY MYPI20081426 patent/MY151064A/en unknown
- 2006-11-04 PL PL12172001T patent/PL2500030T5/pl unknown
- 2006-11-04 KR KR1020197006092A patent/KR20190026048A/ko not_active Application Discontinuation
- 2006-11-04 KR KR1020157011618A patent/KR20150055628A/ko not_active Application Discontinuation
- 2006-11-04 EP EP17186993.6A patent/EP3299027A1/en not_active Withdrawn
- 2006-11-04 KR KR1020137030524A patent/KR20130137716A/ko not_active Application Discontinuation
- 2006-11-04 PT PT121720015T patent/PT2500030E/pt unknown
- 2006-11-04 BR BRPI0619657-8A patent/BRPI0619657A2/pt not_active IP Right Cessation
- 2006-11-04 SG SG10201804008UA patent/SG10201804008UA/en unknown
- 2006-11-04 CN CN201711120837.XA patent/CN107929731A/zh active Pending
- 2006-11-04 CA CA2624393A patent/CA2624393C/en not_active Expired - Fee Related
- 2006-11-04 UA UAA200807619A patent/UA99591C2/ru unknown
- 2006-11-04 WO PCT/US2006/043103 patent/WO2007056227A2/en active Application Filing
- 2006-11-04 SI SI200631974T patent/SI2500030T2/sl unknown
- 2006-11-04 KR KR1020167036246A patent/KR20170002684A/ko not_active Application Discontinuation
- 2006-11-04 KR KR1020087013385A patent/KR101511787B1/ko active IP Right Grant
- 2006-11-04 EP EP12172001.5A patent/EP2500030B2/en active Active
- 2006-11-04 ES ES12172001.5T patent/ES2551202T5/es active Active
- 2006-11-04 HU HUE12172001A patent/HUE026423T2/en unknown
- 2006-11-04 NZ NZ567483A patent/NZ567483A/en not_active IP Right Cessation
- 2006-11-04 EP EP15172358.2A patent/EP2998318A1/en not_active Withdrawn
-
2008
- 2008-04-01 IL IL190547A patent/IL190547A/en not_active IP Right Cessation
- 2008-04-30 MX MX2018014357A patent/MX2018014357A/es unknown
- 2008-05-03 CR CR10041A patent/CR10041A/es unknown
- 2008-05-30 MA MA30972A patent/MA29976B1/fr unknown
- 2008-06-03 NO NO20082483A patent/NO20082483L/no not_active Application Discontinuation
- 2008-06-04 EC EC2008008500A patent/ECSP088500A/es unknown
-
2009
- 2009-09-04 JP JP2009205369A patent/JP2009280626A/ja active Pending
-
2010
- 2010-12-21 RU RU2010152367/15A patent/RU2583927C2/ru not_active IP Right Cessation
-
2012
- 2012-12-10 JP JP2012269482A patent/JP2013049724A/ja not_active Withdrawn
-
2013
- 2013-01-24 ZA ZA2013/00649A patent/ZA201300649B/en unknown
- 2013-03-14 HK HK13103212.1A patent/HK1175718A1/zh not_active IP Right Cessation
- 2013-06-17 PH PH12013501270A patent/PH12013501270B1/en unknown
-
2014
- 2014-05-06 US US14/270,848 patent/US20140335078A1/en not_active Abandoned
-
2015
- 2015-01-29 JP JP2015015014A patent/JP2015083609A/ja not_active Withdrawn
- 2015-06-08 JP JP2015115473A patent/JP2015157862A/ja active Pending
-
2016
- 2016-09-23 HK HK16111213.0A patent/HK1223106A1/zh unknown
-
2017
- 2017-02-20 JP JP2017028964A patent/JP2017095522A/ja not_active Withdrawn
- 2017-02-26 IL IL250772A patent/IL250772A0/en unknown
- 2017-12-15 US US15/844,391 patent/US20180334495A1/en not_active Abandoned
-
2018
- 2018-11-22 IL IL263237A patent/IL263237A/en unknown
- 2018-12-21 JP JP2018238998A patent/JP2019043963A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2501536C2 (ru) * | 2008-10-28 | 2013-12-20 | Джонсон Энд Джонсон Вижн Кэа, Инк. | Устройство и способ активации компонентов запитываемой энергией офтальмологической линзы |
RU2673036C2 (ru) * | 2014-02-27 | 2018-11-21 | Аллерган, Инк. | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2008122341A (ru) | Применение ингибиторов пути комплемента для лечения глазных болезней | |
CA3000638C (en) | Pd-1 antibodies and uses thereof | |
US10232041B2 (en) | Combination of lenalidomide and polypeptide construct, and uses thereof | |
US20200102394A1 (en) | Anti-cxcr4 antibodies and antibody-drug conjugates | |
US20190002559A1 (en) | Antibodies specific for trop-2 and their uses | |
TR201809967T4 (tr) | Nörit dejenerasyonu ile ilişkili hastalıkların tanısı ve tedavisi için bileşim ve yöntem. | |
US20210363267A1 (en) | Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody | |
JP2016515120A (ja) | 抗アルファvベータ5抗体を用いた急性腎損傷の治療及び予防 | |
JP2015083609A5 (ru) | ||
JP2014502280A (ja) | Cd38を特異的に認識する抗体とボルテゾミブを含有する抗腫瘍性の組合せ | |
US11407840B2 (en) | Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer | |
CA3085656A1 (en) | Lag-3 antibody pharmaceutical composition and use thereof | |
JP2015517512A (ja) | Cd37抗体の更なる薬剤との併用 | |
CN105263962A (zh) | 抗体及用于治疗与雌激素受体相关疾病的方法 | |
US20240050564A1 (en) | Combination therapy using an anti-fucosyl-gm1 antibody | |
RU2015132960A (ru) | Применение ингибиторов пути комплемента для лечения глазных болезней | |
US20240132608A1 (en) | Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody | |
KR20180079232A (ko) | L1cam 단백질에 특이적으로 결합하는 항체 및 피리미딘 유사체 및/또는 플라틴계 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
US20230398118A1 (en) | Methods of treating cardiovascular-related disease | |
US20230372390A1 (en) | Methods of treating lymphopenia | |
WO2022098812A1 (en) | Methods of treating iron overload | |
CN112007034A (zh) | Tlr激动剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途 | |
CN111108121A (zh) | Il-20拮抗剂治疗眼病的用途 | |
WO2009029784A1 (en) | Inhibition of complement and cellular activation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20191105 |